Patent SG-11201407440W-A (SG)
Title: Meningococcus serogroup x conjugate
Inventor: ROMANO MARIA ROSARIA
IPC: G01N30/96
Filed: 2013-05-22
Abstract: (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 28 November 2013 (28.11.2013) WIPOIPCT (10) International Publication Number WO 2013/174832 A1 (51) International Patent Classification: A61K 47/48 (2006.01) G01N30/06 (2006.01) A61K39/095 (2006.01) G01N30/96 (2006.01) A61P 31/04 ( 2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/060447 22 May 2013 (22.05.2013) English (30) Priority Data: 61/650,025 22 May 2012 (22.05.2012) 61/698,677 9 September 2012 (09.09.2012) 61/799,528 15 March 2013 (15.03.2013) English US US us (71) Applicant: NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH). (72) Inventors: ROMANO, Maria Rosaria; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). MICOLI, Francesca; Novartis Vaccines Institute for Global Health, Via Fiorentina 1, 1-53100 Siena (IT). BERTI, Francesco; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). ADAMO, Roberto; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). COSTANTINO, Paolo; Novartis Vaccines and Diagnostics SrL, Via Fiorentina 1, 1-53100 Siena (IT). (74) Agents: EVANS, Stephen John Eves et al.; Novartis Vac­ cines and Diagnostics S.r.L, Via Fiorentina 1, 1-53100 Si­ ena (IT). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a)) CJ m oo •t i> i-H cn i-H o CJ o & (54) Title: MENINGOCOCCUS SEROGROUP X CONJUGATE (57) Abstract: The invention provides a conjugate of a Neisseria meningitidis serogroup X capsular polysaccharide and a carrier molecule. The conjugate typically made is by (a) oxidising primary hydroxyl group in a the capsular polysaccharide, give to an oxid­ ised polysaccharide with an aldehyde group; and (b) coupling the oxidised polysaccharide to a carrier molecule via the aldehyde group, thereby giving the conjugate. The conjugate may be part of an immunogenic composition. This composition may comprise one or more further antigens, particularly capsular polysaccharides from serogroups A, W135, C and Y and conjugated forms there­ of. The composition may be in an aqueous formulation. The composition is useful as a vaccine, e.g. for raising an immune response in a mammal. The invention also provides processes for making the conjugate.